Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00185523 · ClinicalTrials.gov registry record
Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)
A clinical trial, sponsored by Stanford University.
- Terminated
- Registry status
- 88
- Enrollment target
NCT00185523: Clinical Trial study, sponsored by Stanford University.
NCT00185523 is a clinical trial that was terminated before completion, run by Stanford University. The registered enrollment target is 88 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00185523 was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- 88 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the overall and disease free survival of recipients who have received G-CSF mobilized stem cells from HLA matched sibling donors.
Interventions
- PROCEDURE Allogeneic hematopoietic cell transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2002-05 |
| Est. Completion | 2009-04 |
Why NCT00185523 stopped before completion
NCT00185523 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 88 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Allogeneic hematopoietic cell transplantation is the first listed.
NCT00185523 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00185523 about?
NCT00185523 is a clinical study titled "Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)". The purpose of the study is to evaluate the overall and disease free survival of recipients who have received G-CSF mobilized stem cells from HLA matched sibling donors.
What is the current status of trial NCT00185523?
This trial is currently terminated. The enrollment target is 88 participants. The study started on 2002-05. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00185523?
The interventions under investigation include: Allogeneic hematopoietic cell transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00185523?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia